Based on five clinical features (number of family members with melanoma, number of members with multiple primary melanomas, median age at diagnosis, presence of pancreatic cancer, and presence of upper airway cancer), Potjer et al. developed the CDKN2A Mutation (CM) score to predict CDKN2A germline mutation status among melanoma prone families; a CM score > 35 out of 49 possible points was associated with a > 90% probability of a melanoma-prone family sharing a CDKN2A mutation [58]. Here, CDKN2A is linked to melanoma.